Assessment of PD-L1 expression in tumors is used as a diagnostic marker for anti-PD1 therapy in non-small cell lung cancer (NSCLC) and several other malignancies (17, 48). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.